Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis

Anne-Rose W Schut; Emma Lidington; Milea J M Timbergen; Eugenie Younger; Winette T A van der Graaf; Winan J van Houdt; Johannes J Bonenkamp; Robin L Jones; Dirk J Grünhagen; Stefan Sleijfer; Cornelis Verhoef; Spyridon Gennatas; Olga Husson

doi:10.3390/cancers14030709

Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis

Anne-Rose W Schut, Emma Lidington, Milea J M Timbergen, Eugenie Younger, Winette T A van der Graaf, Winan J van Houdt, Johannes J Bonenkamp, Robin L Jones, Dirk J Grünhagen, Stefan Sleijfer, Cornelis Verhoef, Spyridon Gennatas, Olga Husson^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

11 Citations (Scopus)

26 Downloads (Pure)

Abstract

Sporadic desmoid-type fibromatosis (DTF) is a rare, non-metastasising soft-tissue tumour. Patients can experience a variety of disease-specific issues related to the unpredictable clinical course and aggressiveness of DTF, which negatively impacts health-related quality of life (HRQoL). These DTF-specific issues are not captured by generic HRQoL tools. A 102-item provisional DTF-specific HRQoL tool, the DTF-QoL, was previously developed. The aim of this study was to pre-test the psychometric properties of the DTF-QoL by administering it together with the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) to 236 DTF patients from the United Kingdom and the Netherlands. Construct validity and reliability were determined based on factor analysis, multi-trait scaling analysis, Cronbach's alpha, and correlations with the EORTC QLQ-C30 scales. Ninety-six items were selected, conceptualised into three symptom scales, eleven disease-impact scales and six single items, together forming the final DTF-QoL. Scaling assumptions were fully or moderately met for ten out of fourteen scales. Cronbach's alpha ranged from 0.551-0.908. Most scales of the DTF-QoL were weakly or moderately correlated with the EORTC QLQ-C30. The DTF-QoL is a promising tool capturing the whole spectrum of DTF-specific issues. Implementation of the DTF-QoL in research and clinical practice will help to personalise HRQoL measurement and clinical care for DTF patients.

Original language	English
Article number	709
Journal	Cancers
Volume	14
Issue number	3
DOIs	https://doi.org/10.3390/cancers14030709
Publication status	Published - 1 Feb 2022

Bibliographical note

Funding Information:
Conflicts of Interest: R.L.J. has received research grants from MSD and GSK and is a consultant for Adaptimmune, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Decipheara, Immunedesign, Lilly, Merck, Pharmacar, Springworks, Tracon and UptoDate. W.T.A.v.d.G. has received research grants from Novartis and Lilly, and advisory board fees from Bayer, and is consultant to Springworks and GSK. All fees to the institute. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Funding Information:
Funding: This research was funded by Stichting Coolsingel, Rotterdam, the Netherlands (grant number 566), the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London (B038). Husson is supported by a Social Psychology Fellowship from the Dutch Cancer Society (#KUN2015-7527) and by a grant from the Netherlands Organisation for Scientific Research (VIDI198.007).

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers14030709Licence: CC BY

cancers-14-00709-v3Final published version, 285 KBLicence: CC BY-NC-ND

Cite this

Schut, A.-R. W., Lidington, E., Timbergen, M. J. M., Younger, E., van der Graaf, W. T. A., van Houdt, W. J., Bonenkamp, J. J., Jones, R. L., Grünhagen, D. J., Sleijfer, S., Verhoef, C., Gennatas, S., & Husson, O. (2022). Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis. Cancers, 14(3), Article 709. https://doi.org/10.3390/cancers14030709

@article{86b265eb70aa49e6a8cc932f8afa4576,

title = "Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis",

abstract = "Sporadic desmoid-type fibromatosis (DTF) is a rare, non-metastasising soft-tissue tumour. Patients can experience a variety of disease-specific issues related to the unpredictable clinical course and aggressiveness of DTF, which negatively impacts health-related quality of life (HRQoL). These DTF-specific issues are not captured by generic HRQoL tools. A 102-item provisional DTF-specific HRQoL tool, the DTF-QoL, was previously developed. The aim of this study was to pre-test the psychometric properties of the DTF-QoL by administering it together with the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) to 236 DTF patients from the United Kingdom and the Netherlands. Construct validity and reliability were determined based on factor analysis, multi-trait scaling analysis, Cronbach's alpha, and correlations with the EORTC QLQ-C30 scales. Ninety-six items were selected, conceptualised into three symptom scales, eleven disease-impact scales and six single items, together forming the final DTF-QoL. Scaling assumptions were fully or moderately met for ten out of fourteen scales. Cronbach's alpha ranged from 0.551-0.908. Most scales of the DTF-QoL were weakly or moderately correlated with the EORTC QLQ-C30. The DTF-QoL is a promising tool capturing the whole spectrum of DTF-specific issues. Implementation of the DTF-QoL in research and clinical practice will help to personalise HRQoL measurement and clinical care for DTF patients.",

author = "Schut, {Anne-Rose W} and Emma Lidington and Timbergen, {Milea J M} and Eugenie Younger and {van der Graaf}, {Winette T A} and {van Houdt}, {Winan J} and Bonenkamp, {Johannes J} and Jones, {Robin L} and Gr{\"u}nhagen, {Dirk J} and Stefan Sleijfer and Cornelis Verhoef and Spyridon Gennatas and Olga Husson",

note = "Funding Information: Conflicts of Interest: R.L.J. has received research grants from MSD and GSK and is a consultant for Adaptimmune, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Decipheara, Immunedesign, Lilly, Merck, Pharmacar, Springworks, Tracon and UptoDate. W.T.A.v.d.G. has received research grants from Novartis and Lilly, and advisory board fees from Bayer, and is consultant to Springworks and GSK. All fees to the institute. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Funding Information: Funding: This research was funded by Stichting Coolsingel, Rotterdam, the Netherlands (grant number 566), the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London (B038). Husson is supported by a Social Psychology Fellowship from the Dutch Cancer Society (#KUN2015-7527) and by a grant from the Netherlands Organisation for Scientific Research (VIDI198.007). Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = feb,

day = "1",

doi = "10.3390/cancers14030709",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

Schut, A-RW, Lidington, E, Timbergen, MJM, Younger, E, van der Graaf, WTA, van Houdt, WJ, Bonenkamp, JJ, Jones, RL, Grünhagen, DJ , Sleijfer, S , Verhoef, C, Gennatas, S & Husson, O 2022, 'Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis', Cancers, vol. 14, no. 3, 709. https://doi.org/10.3390/cancers14030709

TY - JOUR

T1 - Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis

AU - Schut, Anne-Rose W

AU - Lidington, Emma

AU - Timbergen, Milea J M

AU - Younger, Eugenie

AU - van der Graaf, Winette T A

AU - van Houdt, Winan J

AU - Bonenkamp, Johannes J

AU - Jones, Robin L

AU - Grünhagen, Dirk J

AU - Sleijfer, Stefan

AU - Verhoef, Cornelis

AU - Gennatas, Spyridon

AU - Husson, Olga

N1 - Funding Information: Conflicts of Interest: R.L.J. has received research grants from MSD and GSK and is a consultant for Adaptimmune, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Decipheara, Immunedesign, Lilly, Merck, Pharmacar, Springworks, Tracon and UptoDate. W.T.A.v.d.G. has received research grants from Novartis and Lilly, and advisory board fees from Bayer, and is consultant to Springworks and GSK. All fees to the institute. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Funding Information: Funding: This research was funded by Stichting Coolsingel, Rotterdam, the Netherlands (grant number 566), the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London (B038). Husson is supported by a Social Psychology Fellowship from the Dutch Cancer Society (#KUN2015-7527) and by a grant from the Netherlands Organisation for Scientific Research (VIDI198.007). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/2/1

Y1 - 2022/2/1

N2 - Sporadic desmoid-type fibromatosis (DTF) is a rare, non-metastasising soft-tissue tumour. Patients can experience a variety of disease-specific issues related to the unpredictable clinical course and aggressiveness of DTF, which negatively impacts health-related quality of life (HRQoL). These DTF-specific issues are not captured by generic HRQoL tools. A 102-item provisional DTF-specific HRQoL tool, the DTF-QoL, was previously developed. The aim of this study was to pre-test the psychometric properties of the DTF-QoL by administering it together with the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) to 236 DTF patients from the United Kingdom and the Netherlands. Construct validity and reliability were determined based on factor analysis, multi-trait scaling analysis, Cronbach's alpha, and correlations with the EORTC QLQ-C30 scales. Ninety-six items were selected, conceptualised into three symptom scales, eleven disease-impact scales and six single items, together forming the final DTF-QoL. Scaling assumptions were fully or moderately met for ten out of fourteen scales. Cronbach's alpha ranged from 0.551-0.908. Most scales of the DTF-QoL were weakly or moderately correlated with the EORTC QLQ-C30. The DTF-QoL is a promising tool capturing the whole spectrum of DTF-specific issues. Implementation of the DTF-QoL in research and clinical practice will help to personalise HRQoL measurement and clinical care for DTF patients.

AB - Sporadic desmoid-type fibromatosis (DTF) is a rare, non-metastasising soft-tissue tumour. Patients can experience a variety of disease-specific issues related to the unpredictable clinical course and aggressiveness of DTF, which negatively impacts health-related quality of life (HRQoL). These DTF-specific issues are not captured by generic HRQoL tools. A 102-item provisional DTF-specific HRQoL tool, the DTF-QoL, was previously developed. The aim of this study was to pre-test the psychometric properties of the DTF-QoL by administering it together with the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) to 236 DTF patients from the United Kingdom and the Netherlands. Construct validity and reliability were determined based on factor analysis, multi-trait scaling analysis, Cronbach's alpha, and correlations with the EORTC QLQ-C30 scales. Ninety-six items were selected, conceptualised into three symptom scales, eleven disease-impact scales and six single items, together forming the final DTF-QoL. Scaling assumptions were fully or moderately met for ten out of fourteen scales. Cronbach's alpha ranged from 0.551-0.908. Most scales of the DTF-QoL were weakly or moderately correlated with the EORTC QLQ-C30. The DTF-QoL is a promising tool capturing the whole spectrum of DTF-specific issues. Implementation of the DTF-QoL in research and clinical practice will help to personalise HRQoL measurement and clinical care for DTF patients.

UR - http://www.scopus.com/inward/record.url?scp=85123517768&partnerID=8YFLogxK

U2 - 10.3390/cancers14030709

DO - 10.3390/cancers14030709

M3 - Article

C2 - 35158976

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 3

M1 - 709

ER -

Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this